z-logo
Premium
An anti‐apoptotic protein, Hax‐1, inhibits the HIV‐1 rev function by altering its sub‐cellular localization
Author(s) -
Modem Suhasini,
Reddy Thipparthi R.
Publication year - 2008
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.21305
Subject(s) - nuclear export signal , cytoplasm , rna , messenger rna , microbiology and biotechnology , rna binding protein , in vitro , apoptosis , biology , cell nucleus , chemistry , gene , biochemistry
The human immunodeficiency virus type 1 (HIV‐1) Rev protein facilitates the nuclear export of viral mRNA containing the Rev response element (RRE). Although several host proteins co‐operating with Rev in viral RNA export have been reported, little is known about the innate host defense factors that Rev overcomes to mediate the nuclear export of unspliced viral mRNAs. We report here that an anti‐apoptotic protein, HS1‐associated protein X‐1 (Hax‐1), a target of HIV‐1 Vpr, interacts with Rev and inhibits its activity in RRE‐mediated gene expression. Co‐expression of Sam68 emancipates Rev activity from Hax‐1‐mediated inhibition. Hax‐1 does not bind to RRE RNA by itself, but inhibits Rev from binding to RRE RNA in vitro. The impact of Hax‐1 on Rev/RRE interactions in vitro correlates well with the reduced level of RRE‐containing mRNA in vivo. Immunofluorescence studies further reveal that Hax‐1 and Rev are cytoplasmic and nuclear proteins, respectively, when expressed independently. However, in Hax‐1 co‐expressing cells, Rev is translocated from the nucleus to the cytoplasm, where it is co‐localized with Hax‐1 in the cytoplasm. We propose that over‐expression of Hax‐1, possibly through binding to Rev, may interfere with the stability/export of RRE‐containing mRNA and target the RNA for degradation. J. Cell. Physiol. 214:14–19, 2008. © 2007 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here